Literature DB >> 1323601

Infrequent point mutations in codons 12 and 61 of ras oncogenes in human hepatocellular carcinomas.

C Challen1, K Guo, J D Collier, D Cavanagh, M F Bassendine.   

Abstract

DNA from human hepatocellular carcinomas (HCC) were analysed for the presence of mutations in codons 12 and 61 of the K-ras, H-ras and N-ras genes. The relevant ras sequences were amplified in vitro using the polymerase chain reaction and point mutations detected by selective hybridisation using mutation-specific synthetic oligonucleotides. In one of the 19 HCCs a mutation in codon 61 of the K-ras gene was detected, whilst in 3/19 HCCs a mutation was found in codon 61 of the N-ras gene. The mutations were all heterozygous A-T transversions and were found in HCCs arising in patients with underlying cirrhosis. In two of these patients where the corresponding normal tissue was available only the wild-type ras gene was detected, indicating that oncogenic activation of the ras gene was a consequence of somatic mutation. In another patient the same mutation in codon 61 of the N-ras gene was found in cirrhotic liver tissue and in all four patients the same mutation was also detected in formalin-fixed, paraffin-embedded liver biopsy HCC tissue obtained at diagnosis. These results indicate that mutational activation of the ras genes at codon 61 is an infrequent but possibly early event in the development of HCC in Britain.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1323601     DOI: 10.1016/0168-8278(92)90181-n

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  22 in total

Review 1.  Genetics of hepatocellular carcinoma.

Authors:  Andreas Teufel; Frank Staib; Stephan Kanzler; Arndt Weinmann; Henning Schulze-Bergkamen; Peter-R Galle
Journal:  World J Gastroenterol       Date:  2007-04-28       Impact factor: 5.742

Review 2.  Molecular classification and novel targets in hepatocellular carcinoma: recent advancements.

Authors:  Yujin Hoshida; Sara Toffanin; Anja Lachenmayer; Augusto Villanueva; Beatriz Minguez; Josep M Llovet
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

3.  Synergistic role of Sprouty2 inactivation and c-Met up-regulation in mouse and human hepatocarcinogenesis.

Authors:  Susie A Lee; Sara Ladu; Matthias Evert; Frank Dombrowski; Valentina De Murtas; Xin Chen; Diego F Calvisi
Journal:  Hepatology       Date:  2010-08       Impact factor: 17.425

4.  Inactivation of Spry2 accelerates AKT-driven hepatocarcinogenesis via activation of MAPK and PKM2 pathways.

Authors:  Chunmei Wang; Salvatore Delogu; Coral Ho; Susie A Lee; Bing Gui; Lijie Jiang; Sara Ladu; Antonio Cigliano; Frank Dombrowski; Matthias Evert; Diego F Calvisi; Xin Chen
Journal:  J Hepatol       Date:  2012-05-19       Impact factor: 25.083

Review 5.  New insights in hepatocellular carcinoma: from bench to bedside.

Authors:  Samuele De Minicis; Marco Marzioni; Antonio Benedetti; Gianluca Svegliati-Baroni
Journal:  Ann Transl Med       Date:  2013-07

6.  Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

Authors:  Pippa Newell; Sara Toffanin; Augusto Villanueva; Derek Y Chiang; Beatriz Minguez; Laia Cabellos; Radoslav Savic; Yujin Hoshida; Kiat Hon Lim; Pedro Melgar-Lesmes; Steven Yea; Judit Peix; Kemal Deniz; M Isabel Fiel; Swan Thung; Clara Alsinet; Victoria Tovar; Vincenzo Mazzaferro; Jordi Bruix; Sasan Roayaie; Myron Schwartz; Scott L Friedman; Josep M Llovet
Journal:  J Hepatol       Date:  2009-06-12       Impact factor: 25.083

7.  Bmi1 functions as an oncogene independent of Ink4A/Arf repression in hepatic carcinogenesis.

Authors:  Chuan-Rui Xu; Susie Lee; Coral Ho; Prashant Bommi; Shi-Ang Huang; Siu Tim Cheung; Goberdhan P Dimri; Xin Chen
Journal:  Mol Cancer Res       Date:  2009-11-24       Impact factor: 5.852

8.  New pharmacological developments in the treatment of hepatocellular cancer.

Authors:  Niraj J Gusani; Yixing Jiang; Eric T Kimchi; Kevin F Staveley-O'Carroll; Hua Cheng; Jaffer A Ajani
Journal:  Drugs       Date:  2009       Impact factor: 9.546

9.  Central role of c-Myc during malignant conversion in human hepatocarcinogenesis.

Authors:  Pal Kaposi-Novak; Louis Libbrecht; Hyun Goo Woo; Yun-Han Lee; Nathaniel C Sears; Cedric Coulouarn; Elizabeth A Conner; Valentina M Factor; Tania Roskams; Snorri S Thorgeirsson
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

10.  A rare point mutation in the Ras oncogene in hepatocellular carcinoma.

Authors:  Akinobu Taketomi; Ken Shirabe; Jun Muto; Shohei Yoshiya; Takashi Motomura; Yohei Mano; Tohru Ikegami; Tomoharu Yoshizumi; Kenji Sugio; Yoshihiko Maehara
Journal:  Surg Today       Date:  2012-12-26       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.